Long-term side effects of glucocorticoids

References

• Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc. 1949;24:181–197.
   PubMed Web of Science ®Google Scholar
• Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever, and certain other conditions. Arch Intern Med (Chic). 1950;85:545–666.
   PubMedGoogle Scholar
• Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203–207.
   PubMedGoogle Scholar
• Van der Goes M, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases-positive and adverse effects. Arthritis Res Ther. 2014;16 Suppl 2:S2.
   Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420–426.
   PubMed Web of Science ®Google Scholar
• Pereira RM, Carvalho JF, Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo). 2010;65:1197–1205.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000.
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum. 2000;43:522–530.
   PubMed Web of Science ®Google Scholar
• De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med. 2008;99:23–43.
   PubMedGoogle Scholar
• Daens S, Peretz A, de Maertelaer V, et al. Efficiency of quantitative ultrasound measurements as compared with dual-energy x-ray absorptiometry in the assessment of corticosteroid-induced bone impairment. Osteoporos Int. 1999;10:278–283.
   PubMed Web of Science ®Google Scholar
• Hooyman JR, Melton LJ, Nelson AM, et al. Fractures after rheumatoid arthritis – a population based study. Arthritis Rheum. 1984;27:1353–1361.
   PubMed Web of Science ®Google Scholar
• Baranova IA, Ershova OB, Anaev EK. Analysis of the state-of-the-art of consulting medical care to patients with glucocorticoid-induced osteoporosis or its risk according to the data of a questionnaire survey (GLUCOST study). Ter Arkh. 2015;87:58–64.
   PubMed Web of Science ®Google Scholar
• Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol. 2007;26:144–153.
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41:595–611.
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41:183–190.
   PubMed Web of Science ®Google Scholar
• Cushing H. The basophil adenoma of the pituitary body and their clinical manifestation. Johns Hopkins Med. 1932;50:137.
   Google Scholar
• Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197:1–10.
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci. 1976;271:202–210.
   PubMed Web of Science ®Google Scholar
• McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev. 1988;4:17–30.
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Scandali VM, Trementino L, et al. Pathophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):86–90.
   PubMed Web of Science ®Google Scholar
• Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53:528–535.
   PubMed Web of Science ®Google Scholar
• Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–293.
   PubMed Web of Science ®Google Scholar
• Braith RW, Welsch MA, Mills RM Jr, et al. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc. 1988;30:483–489.
   Web of Science ®Google Scholar
• Aceto T, Beckhorn GD, Jorgensen JR, et al. Iatrogenic ACTH-cortisol insufficiency. Pediatr Clin North Am. 1966;13:543–557.
   Web of Science ®Google Scholar
• Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–740.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–796.
   PubMed Web of Science ®Google Scholar
• Hill RB Jr. Fatal fat embolism from steroid-induced fatty liver. N Engl J Med. 1961;265:318–320.
   Web of Science ®Google Scholar
• Sadr-Azodi O, Mattsson F, Bexlius TS, et al. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med. 2013;173:444–449.
   PubMed Web of Science ®Google Scholar
• Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta- analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–632.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119–1124.
   PubMed Web of Science ®Google Scholar
• Sato A, Funder JW, Okubo M, et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens. 1995;8:823–828.
   PubMed Web of Science ®Google Scholar
• Fardet L, Feve B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs. 2014;74:1731–1745.
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764–770.
   PubMed Web of Science ®Google Scholar
• McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170–1175.
   PubMed Web of Science ®Google Scholar
• Van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166:1016–1020.
   PubMed Web of Science ®Google Scholar
• Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart. 2004;90:859–865.
   PubMed Web of Science ®Google Scholar
• Werth VP. Management and treatment with systemic glucocorticoids. Adv Dermatol. 1993;8:81–103.
   PubMedGoogle Scholar
• Kaya G. New therapeutic targets in dermatoporosis. J Nutr Health Aging. 2012;16:285–288.
   PubMed Web of Science ®Google Scholar
• Kaya G, Saurat JH. Dermatoporosis: a chronic cutaneous insufficiency/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. Dermatology. 2007;215:284–294.
   PubMed Web of Science ®Google Scholar
• Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3:17–21.
   PubMedGoogle Scholar
• Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157:142–148.
   PubMed Web of Science ®Google Scholar
• Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology. 1999;21:474–484.
   PubMed Web of Science ®Google Scholar
• Barrimi M, Aalouane R, Aarab C, et al. [Prolonged corticosteroid-therapy and anxiety-depressive disorders, longitudinal study over 12 months]. Encephale. 2013;39:59–65.
   PubMed Web of Science ®Google Scholar
• Boston Collaborative Drug Study. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972;13:694–698.
   PubMed Web of Science ®Google Scholar
• Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord. 1983;5:319–332.
   PubMed Web of Science ®Google Scholar
• Fel A, Aslangul E, Le Jeunne C. [Eye and corticosteroid’s use]. Presse Med. 2012;41:414–421.
   PubMed Web of Science ®Google Scholar
• James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23:403–420.
   PubMed Web of Science ®Google Scholar
• Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15:439–450.
   PubMed Web of Science ®Google Scholar
• Miller D, Peczon JD, Whitworth CG. Corticosteroids and functions in the anterior segment of the eye. Am J Ophthalmol. 1965;59:31–34.
   PubMed Web of Science ®Google Scholar
• Haimovici R, Koh S, Gagnon DR, et al. Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111:244–249.
   PubMed Web of Science ®Google Scholar
• Dale DC, Petersdorf RG. Corticosteroids and infectious diseases. Med Clin North Am. 1973;57:1277–1287.
   PubMed Web of Science ®Google Scholar
• Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963.
   PubMedGoogle Scholar
• Grossi O, Genereau T. [Glucocorticoids and infections, doping, surgery, sexuality]. Rev Med Interne. 2013;34:269–278.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69:1913–1919.
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–2381.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville (MD): U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
   Google Scholar
• American College of Rheumatology. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496–1503.
   PubMedGoogle Scholar
• Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560–1567.
   PubMed Web of Science ®Google Scholar
• Schacke H, Berger M, Rehwinkel H, et al. Selective glucocorticoid receptor agonists (SE GRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275:109–117.
   PubMed Web of Science ®Google Scholar
• Reuter KC, Grunwitz CR, Kaminski BM, et al. Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther. 2012;341:68–80.
   PubMed Web of Science ®Google Scholar
• Quan L, Zhang Y, Crielaard BJ, et al. Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano. 2014;8:458–466.
   PubMed Web of Science ®Google Scholar
• Elbialy NS, Abdol-Azim BM, Shafaa MW, et al. Enhancement of the ocular therapeutic effect of prednisolone acetate by liposomal entrapment. J Biomed Nanotechnol. 2013;9:2105–2116.
   PubMed Web of Science ®Google Scholar